Most of the p53 target genes, all except MDM2, COP1 and PIRH2, perform functions in apoptosis, differentiation and cell cycle arrest. The aforementioned oncogenes downregulate p53 through a negative feedback mechanism, and thus contribute to tumor development. In this study, we report a new p53 target, PRL-1, which is believed to be a significant regulator in the development and metastasis of a variety of cancer types. Phosphatase of regenerating liver 1 (PRL-1) overexpression reduced the levels of endogenous and exogenous p53 proteins, and inhibited p53-mediated apoptosis. On the other hand, the ablation of PRL-1 by small interfering RNA (siRNA) increased p53 protein levels. The p53 downregulation was mediated by p53 ubiquitination and subsequent proteasomal degradation. Furthermore, p53 ubiquitination by PRL-1 was achieved through two independent pathways, by inducing PIRH2 transcription and by inducing MDM2 phosphorylation through Akt signaling. In addition, we showed that the PRL-1 gene harbors a p53 response element in the first intron, and its transcription is regulated by the p53 protein. These findings imply that the new oncogenic p53 target, PRL-1, may contribute to tumor development by the downregulation of p53 by a negative feedback mechanism.
Introduction
The p53 signaling pathway performs a function in a number of cell signaling pathways, including cell cycle arrest, apoptosis, anti-angiogenesis and DNA repair (Balint and Vousden, 2001) . Therefore, many p53 target genes have been shown to be involved in tumor suppression, with the notable exception of MDM2, PIRH2 and COP1 genes. These oncogenes are cellular ubiquitin-protein ligases and regulate p53 through ubiquitination, which results in its proteasomal degradation (Leng et al., 2003; Li et al., 2003; Dornan et al., 2004) . Their direct binding to p53 by a feedback mechanism has been shown to contribute to tumor development. This may be one reason why p53 is involved in the transcription of oncogenes to be selfcontrolled by target genes.
The phosphatase of regenerating liver (PRL) family is a group of protein tyrosine phosphatases that play a significant role in the development and metastasis of a variety of cancer types (Stephens et al., 2005; Achiwa and Lazo, 2007) . Within this family, PRL-1, PRL-2 and PRL-3, share a high degree of sequence similarity. The increased expression of PRLs has been observed in a variety of cancers, including colorectal cancer (Saha et al., 2001) , prostate cancer (Wang et al., 2002) , breast cancer (Parker et al., 2004) , gastric cancer (Miskad et al., 2004) and liver cancer (Wu et al., 2004) , and particularly in metastatic cancers (Stephens et al., 2005) . Their ectopic expression in non-tumorigenic cells promotes proliferation, migration and invasion (Saha et al., 2001; Wu et al., 2004; Wang et al., 2007) .
The effects of PRLs on cell growth and cancer development are mediated through a number of signaling pathways (see Figure 5 ). PRL-1 and PRL-3 promote the activation of the Rho GTPases RhoA and RhoC, and signaling through Rho kinase eventually activates serum response factor (Fiordalisi et al., 2006) . Serum response factor, a transcription factor that binds to a serum response element, is associated with a variety of genes, including immediate early genes including c-fos, fosB, egr1 (Qureshi et al., 1991) and egr2 (Gius et al., 1990) . The EGR family is expressed in a wide range of cell types (Gashler and Sukhatme, 1995; Yoo and Lee, 2004) , and members of that family harbor a highly similar DNA-binding domain, which recognizes an identical DNA response element (Gashler and Sukhatme, 1995) . Among the EGR family members, the best characterized is EGR1, which has been implicated in the regulation of immune effectors (McMahon and Monroe, 1996) , cancer progression and metastasis (Kobayashi et al., 2002) .
The phosphates and tensin homolog downregulated by PRL-3 is a tumor suppressor and inhibits the phosphatidylinositol 3-kinase (PI3K) pathway, and signals through PI3K to promote the epithelialmesenchymal transition . Thus, PRL-3 induces PI3K signaling, leading to Akt phosphorylation at the Ser 473 residue and promotes cell survival and oncogenesis . PRL-1 and PRL-2 enhance the cell cycle by an increase in cyclindependent kinase 2 activity, and markedly lower levels of the p21 protein (Werner et al., 2003) .
The effects of PRLs on p21 expression (Werner et al., 2003) and Akt phosphorylation suggest that PRLs may be correlated with the levels of the p53 protein regulating p21 expression and related with AKT signaling-mediated MDM2 phosphorylation. Therefore, we investigated the potential relationship between PRL-1 and p53, and detected another exceptional p53 target, PRL-1, which is related with tumorigenesis and cancer metastasis, and negatively regulates p53.
Results

PRL-1 downregulates p53 reporter activity
The PRL-1 gene is associated with tumorigenesis and metastasis in a variety of cancer types. Its overexpression increases cell motility and proliferation through the downregulation of p21 expression (Werner et al., 2003) . Thus, we first attempted to unravel the molecular mechanisms underlying the downregulation of p21 through PRL-1-mediated oncogenesis. To determine the effect of PRL-1 expression on the transcription of p21, HCT116 p53 ( þ / þ ) cells were transfected with a PRL-1 expression plasmid (FLAG-PRL-1) and a wildtype p21-luciferase reporter (Wt p21-luc) or mutant-type p21-luciferase reporter (Mt p21-luc) without the p53 consensus sequence (Figure 1a ). Increasing amounts of PRL-1 markedly reduced the activities of both p21-luc reporters, but the reduction of Wt p21-luc reporter activity was greater than that of Mt p21-luc reporter activity. This suggests that a p53-dependent and p53-independent mechanism may be responsible for the effects of PRL-1 on p21 transactivation. In order to again evaluate the p53 dependency of PRL-1 effects, we analysed the effects of PRL-1 overexpression on a p53 luciferase reporter (pRGC-luc) harboring multiple p53 consensus sequences. Increasing amounts of PRL-1 reduced the activity of pRGC-luc only in HCT116 p53 ( þ / þ ) cells (Figure 1b) , thereby suggesting that PRL-1 inhibits the ability of p53 to transactivate the p53 reporter, as well as the p21 promoter reporter.
PRL-1 overexpression reduces the level of endogenous and exogenous p53 protein We then attempted to determine whether PRL-1 can modulate endogenous or ectopically expressed p53 protein in HCT116 p53 ( þ / þ ) and HCT116 p53 (À/À) cells by transfecting Flag-PRL-1, respectively. Interestingly, in HCT116 p53 ( þ / þ ) cells, transfection with Flag-PRL-1 reduced endogenous p53 protein to a level similar to that observed with the transfection of MDM2 (Figure 1c ). The transfection of Flag-PRL-1 also reduced the level of exogenous p53 protein in HCT116 p53 (À/À) cells in a dose-dependent manner (Figure 1d ). This reduction of p53 by PRL-1 was directly confirmed by microscopic observation in HCT116 p53 ( þ / þ ) and 293A cells transfected transiently with Flag-PRL-1 (Figure 1e ). Endogenous p53 protein (red color) in PRL-1-expressing cells (green color) was reduced as compared with that in nontransfected cells (Figure 1e) .
To confirm the role of PRL-1 in the regulation of p53, endogenous PRL-1 was subjected to ablation by small interfering RNA (siRNA), and the effect on the endogenous p53 protein level was assessed (Figure 1f ). PRL-1 depletion by siRNA in HCT116 p53 ( þ / þ ) ( Figure 1f ) and U2OS cells (data not shown) resulted in a pronounced accumulation of p53 protein, thereby indicating that PRL-1 negatively regulates p53 in unstressed cells. Cells were co-transfected with mock DNA, MDM2 or increasing amounts of FLAG-PRL-1 (100, 300 or 600 ng) in the presence of a constant amount of p53 (300 ng). After transfection, the cells were incubated for 24 h and subjected to immunoblot analysis using the antibodies indicated at right. Tubulin was immunoblotted as a loading control. (e) PRL-1 reduces p53 staining in HCT116 p53 ( þ / þ ) and 293A cells. Cells were transiently transfected with 1 mg of FLAG-PRL-1, incubated for 48 h and labeled with mouse anti-p53 and rabbit anti-PRL-1 antibodies. The cells were then incubated with Alexa Fluor 488-conjugated goat antibody to mouse IgG and Alexa Fluor 594-conjugated goat antibody to rabbit IgG, and microscopy images were acquired. PRL-1, green; p53, red. Scale bars represent 20 and 5 mm for HCT116 p53 ( þ / þ ) and 293A cells, respectively. (f) A reduction in PRL-1 expression by siRNA increases the stability of p53 protein. HCT116 p53 ( þ / þ ) cells were transfected with control siRNA (100 nM) or with increasing amounts of PRL-1 siRNA (10, 50 or 100 nM), incubated for 24 h and subjected to immunoblot analysis using the antibodies indicated at right for immunoblotting. Tubulin was immunoblotted as a loading control.
Effect of PRL-1 on the reduction of p53 is mediated by ubiquitination through the induction of PIRH2 transcription by the induction of EGR1/2 and Mdm2 phosphorylation To assess the mechanism underlying p53 reduction by PRL-1, quantitative reverse transcription PCR (RT-PCR) was conducted on the p53 gene in order to determine whether PRL-1 inhibits p53 transcription. The transfection of Flag-PRL-1 in HeLa, HCT116 p53 ( þ / þ ) or U2OS cells resulted in no significant changes in p53 mRNA levels (Figure 3a) . In contrast, when exogenous p53 was expressed with PRL-1 in the presence or absence of the proteasome inhibitor MG132 in an effort to investigate p53 protein stability, p53 protein rapidly degraded in the absence of MG132 together with an increase in the levels of PRL-1 in HCT116 p53 (À/À) cells (Figure 2a ), but did not change in the presence of this inhibitor. These results show that PRL-1 regulates p53 protein stability, probably through proteasome-mediated degradation.
To determine whether p53 ubiquitination is regulated by PRL-1 in vivo, HCT116 p53 (À/À) cells were 
PRL-1 Mdm2
Mock
co-transfected with the p53, FLAG-PRL-1 and HAubiquitin ( Figure 2b ); immunoprecipitation with anti-p53 antibody and immunoblotting with anti-HA antibody revealed the presence of ubiquitinated p53 when either FLAG-PRL-1 or the positive control MDM2 was present, thus suggesting that PRL-1 induces p53 degradation through ubiquitination.
To further explore the regulation of p53 by PRL-1, we first determined the mRNA levels of known direct p53-negative regulators that ubiquitinate p53, such as MDM2, PIRH2 and COP1, in HeLa cells transfected with or without PRL-1. Among them, the mRNA level of PIRH2, a p53-induced ubiquitin-protein ligase that promotes p53 degradation, was increased in PRL-1-transfected HeLa cells (Figure 3a) . Therefore, we assessed the genomic sequence of PIRH2 encompassing the first 2 exons and 5 kb upstream of the first exon in order to identify potential transcription factor binding sites responsible for the induction of PIRH2 expression. A potential EGR1-(a direct target of serum response factor; Qureshi et al., 1991) binding site was detected within the first intron of PIRH2 from nucleotides þ 1393 to þ 1404 relative to the translational start site (sequence; CCGCCCCCCCCCC). As PRL-1 regulates serum response factor (Fiordalisi et al., 2006) , we attempted to determine whether the EGR1-binding site was responsible for the observed induction of PIRH2 by PRL-1. Therefore, we simultaneously measured the mRNA levels of PIRH2, EGR1 and EGR2 (Figure 3a) , and confirmed the transcriptional induction of these three genes in PRL-1-transfected HeLa cells. However, we detected no EGR3 induction (data not shown). In contrast, the ablation of PRL-1 by siRNA transfection in HCT116 p53 ( þ / þ ) cells resulted in reduced levels of EGR1 and PIRH2 mRNA ( Figure 3b , left panel, and Figure 3c ) and protein ( Figure 3b , right panel). Similar results were noted in 293A and HeLa cells (data not shown). To determine whether EGR1 directly affects the regulation of PIRH2 transcription, we transfected EGR1 siRNA into HCT116 p53 ( þ / þ ) cells and measured the mRNA and protein levels of PIRH2. A reduction in EGR1 by siRNA reduced the levels of PIRH2 mRNA ( Figure 3d , left panel) and protein ( Figure 3d , right panel), and similar results were noted in 293A and HeLa cells (data not shown). In addition, we examined the binding ability of EGR1 in the PIRH2 intron 1 site using a chromatin immunoprecipitation (ChIP) assay. HCT116 p53 ( þ / þ ) cells were subjected to ChIP analysis through immunoprecipitation with or without an EGR1-specific antibody, followed by the PCR analysis of the PIRH2 intron 1 region surrounding the EGR response element. The data presented in Figure 3e indicated that the PIRH2 intron 1 was bound by EGR1 in vivo. As a control, a region of SNAIL genomic DNA harboring an EGR-binding site was bound by EGR1 in vivo, whereas exon 4 of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was not. Similar results were observed in HCT116 p53 (À/À) cells (data not shown). These findings indicate that EGR1, which is controlled by PRL-1, is involved in the transcriptional activation of PIRH2.
As the function of PRL-3 has been showed to be similar to that of PRL-1 (Stephens et al., 2005; Fiordalisi et al., 2006; Achiwa and Lazo, 2007) , we attempted to determine whether PRL-1, like PRL-3, can regulate the PI3K signal and increase Ser 473 phosphorylation of AKT, which, in turn, phosphorylates Mdm2 at Ser 166 (Milne et al., 2004) . We determined that the transfection of HCT116 p53 ( þ / þ ) cells with Flag-PRL-1 activated AKT, as was indicated by increased Ser 473 phosphorylation, and even promoted MDM2 phosphorylation, resulting in the stabilization of MDM2 and the downregulation of p53 protein (Figure 3f ). Similar results were noted in colon carcinoma DLD1 cells and in U2OS cells (data not shown). Furthermore, the phosphorylation-enhancing effects of PRL-1 on AKT and MDM2 in cells were blocked by the PI3K inhibitor LY294002 (Figure 3f ). (1 mmol/l) for 6 h. Cell extracts were prepared 24 h later and ubiquitinated p53 was detected through immunoprecipitation using anti-p53 antibody followed by SDS-polyacrylamide gel electrophoresis and immunoblot analysis using anti-HA antibody. Cell lysates were subjected to immunoblot analysis using the antibodies indicated b-actin and Flag.
PRL-1 is a new negative feedback regulator of p53 S-H Min et al (a) Overexpression of PRL-1 induces PIRH2 and EGR1 transcription. HeLa cells were transfected with 1 mg of mock DNA (À) or FLAG-PRL-1 ( þ ) and incubated for 24 h. RNA was isolated and subjected to quantitative reverse transcription PCR (RT-PCR) (left pannel) and real-time PCR (graphs at right pannel) using primers specific for EGR1, EGR2, p53, PRL-1, PIRH2 or GAPDH (control) transcripts. The sample value was calculated as the difference between GAPDH and sample values. (b) Ablation of PRL-1 by siRNA decreases the level of Pirh2. HCT116 p53 ( þ / þ ) cells were transfected with PRL-1 siRNA ( þ , 10nM; þ þ , 50 nM) or control siRNA (À) and analysed by quantitative RT-PCR (left panel) using primers specific for EGR1, PRL-1, PIRH2 or GAPDH transcripts followed by agarose gel electrophoresis, and by western blotting (right panel) using antibodies against EGR1, PRL-1, PIRH2 and GAPDH. (c) Ablation of PRL-1 by siRNA decreases the level of EGR1 and PIRH2. cDNAs of Figure 3b were subjected to real-time PCR using primers specific for EGR1, PRL-1, PIRH2 or GAPDH (control) transcripts. The sample value was calculated as the difference between GAPDH and sample values.
(d) Ablation of EGR1 by siRNA reduces the level of PIRH2. HCT116 p53 ( þ / þ ) cells were transfected with EGR1 siRNA ( þ , 10 nM; þ þ , 50 nM) or control siRNA (À) and analysed through quantitative RT-PCR (left panel) using primers specific for EGR1, PIRH2 or b-actin transcripts followed by agarose gel electrophoresis, and by western blotting (right panel) using antibodies against EGR1, PIRH2 and b-actin. (e) EGR1 binds to the EGR response element of PIRH2 in vivo. HCT116 p53 ( þ / þ ) cells were subjected to chromatin immunoprecipitation (ChIP) analysis. Immunoprecipitation of EGR1 protein-DNA complexes was performed with control IgG or anti-EGR1 antibody. Input, 0.1% of the sonicated chromatin prior to immunoprecipitation. After immunoprecipitation, PCR amplification was conducted using primers specific for intron 1 of PIRH2. As controls, primers specific for the genomic region harboring the EGR-responsive element of SNAIL, a known EGR1 target gene, and primers specific for exon 4 of GAPDH were used. The displayed results are representative of three independent experiments. (f) PRL-1 overexpression promotes MDM2 phosphorylation through the activation of Akt. HCT116 p53 ( þ / þ ) cells were transfected with 1 mg of mock DNA or FLAG-PRL-1 expression plasmid, incubated for 24 h and treated for 4-6 h with or without the PI3K inhibitor LY294002. Cell extracts were subjected to immunoblot analysis using the antibodies indicated at right. (g) Effects of PIRH2 or MDM2 ablation on PRL-1-dependent downregulation of p53. HeLa cells were transfected with indicated DNA (0.3 mg) and siRNA (30 nm), and incubated for 24 h. Cell extracts were subjected to immunoblot analysis using the antibodies indicated at right. (h) PRL-1 inhibits p53-mediated apoptosis. HeLa cells were transiently transfected with Flag-PRL-1 as indicated, together with p53 and green fluorescent protein (GFP), and incubated in the presence (gray bars) or absence (white bars) of 5FU (5-fluorouracil). Apoptotic cell death was determined using the GFP expression system, as described in the Materials and methods section. GFP-positive cells were assessed for the presence of apoptotic nuclei with a fluorescence microscope. The data are expressed as the means ± s.d. of duplicate assays and are representative of three independent experiments.
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However, the observed reduction in p53 protein upon treatment with LY294002 is likely attributable to the fact that the treatment of cells with LY294002 has been shown earlier to increase MDM2 transcription (Jeong et al., 2005) and induces proteosome-dependent degradation (Feng et al., 2004) , resulting in the downregulation of p53 and unchanged MDM2 protein levels, but an increase in MDM2 levels. In fact, we confirmed the increase in MDM2 transcription by LY294002 using quantitative RT-PCR (data not shown).
We then conducted a set of experiments designed to determine the effects of PIRH2 or MDM2 ablation on the PRL-1-dependent downregulation of p53 (Figure 3g ). The transfection of HeLa cells with PRL-1 and control siRNA reduced the levels of the p53 protein level and increased the levels of p-AKT, p-MDM2 and PIRH2 as compared with the cells transfected with mock and control siRNA. Both cells transfected with PRL-1 and PIRH2 siRNA or MDM2 siRNA evidenced an increase in p53 protein levels as compared with that seen in the cells transfected with PRL-1 and control siRNA. However, the increased level of p53 by PIRH2 or MDM2 ablation was slightly lower than the p53 level in cells transfected with mock and control siRNA. These findings suggest that the downregulation of p53 by PRL-1 is mediated by two independent proteosomal degradations by means of PIRH2 and MDM2.
We attempted to determine whether PRL-1 expression influences p53-mediated apoptosis and assessed the effects of PRL-1 on p53-mediated apoptosis using a green fluorescent protein (GFP) assay system in HeLa cells. Apoptotic cells were scored by changes in their nuclear morphology among GFP-positive cells after inducing apoptosis by treatment with or without 5-fluorouracil. The addition of PRL-1 resulted in a reduction in p53-mediated apoptosis (Figure 3h) , regardless of the fact that 5-fluorouracil is an inducer of p53-mediated apoptosis (Bunz et al., 1999) .
Intron 1 of PRL-1 contains a potent p53 binding sequence As feedback inhibition is a common mechanism among the molecules of the p53 pathway, we attempted to determine whether p53 regulates PRL-1 gene expression. We evaluated the human genomic sequences encompassing all six exons of PRL-1, including 5 kb of the sequence upstream of the first exon, and determined the presence of a putative p53 binding site within the first intron of PRL-1 from nucleotides þ 1635 to þ 1734 relative to the predicted transcriptional start site ( þ 1) (Figure 4a ). This sequence matched the consensus p53 binding site at 19 of the 20 bp, and did not harbor a spacer between the p53 binding sites. To determine whether p53 activates this putative binding site, we amplified the binding site from the genomic DNA through PCR, inserted it upstream of a luciferase reporter gene in the pGL3-promoter vector and cotransfected the resulting reporter (PRL1-p53-luc) into the HCT116 p53 (À/À) cell line with various amounts of p53 ( Figure 4b ). As a negative control, we prepared a luciferase reporter construct (PRL1 1.1 kb-luc) including the 1.1 kb PRL-1 proximal promoter, which does not harbor the p53 binding site in the pGL3-basic vector (Figure 4b ). The luciferase activity of PRL1 1.1 kb-luc was not altered in the presence of p53, whereas the luciferase activity of PRL1-p53-luc increased in the presence of p53 in a dose-dependent manner. Furthermore, the transfection of the p53 expression plasmid substantially increased PRL-1 mRNA levels in the HCT116 p53 (À/À) cell line (Figure 4c) . In contrast, when p53 was ablated by siRNA transfection in HCT116 p53 ( þ / þ ) cells, decreased expressions of PRL-1 mRNA and protein were detected through quantitative RT-PCR and western blot analysis, respectively (Figure 4d ). We also assessed the binding of endogenous p53 to the PRL-1 intron 1 site using a ChIP assay. HCT116 p53 ( þ / þ ) and HCT116 p53 (À/À) cells were subjected to ChIP analysis through immunoprecipitation with p53-specific antibody, followed by PCR analysis of the of PRL-1 intron 1 region surrounding the p53 response element. The data provided in Figure 4e show that the PRL-1 intron 1 was bound by p53 in vivo. As a control, a region of genomic p21 DNA harboring a p53 binding site was bound by p53 in vivo, whereas GAPDH was not (Weizer-Stern et al., 2007) .
Discussion
PRL-1 (also known as PTP4A1) was originally identified as an immediate early gene in the regenerating liver (Diamond et al., 1994) . Subsequent studies have revealed that PRL-1 may be involved in several biological functions, including proliferation, metastasis and tumorigenesis (Stephens et al., 2005) . Its expression is elevated in several tumor cell lines, and cells expressing high levels of PRL-1 evidence enhanced proliferation and anchorage-independent growth (Werner et al., 2003; Stephens et al., 2005) . Furthermore, cells stably expressing PRL-1 display enhanced motility and invasiveness, and have been shown to induce metastatic tumor formation in mice (Liang et al., 2007) . The results of a recent study revealed that PRL-1 is involved in the downregulation of p21 (Werner et al., 2003) . However, the mechanism by which p21 downregulation is modulated by PRL-1 remains to be clearly elucidated. In this study, we determined that PRL-1 downregulates p21 by a reduction in p53 protein levels. The ectopic expression of PRL-1 reduced the levels of endogenous and exogenous p53 protein. The downregulation of p53 by PRL-1 is mediated by p53 ubiquitination and subsequent proteasomal breakdown. As PRL-1 is a protein tyrosine phosphatase but not a ubiquitin-protein ligase-like MDM2, PIRH2, and COP1, PRL-1 could not mediate the ubiquitination of p53 through a direct mechanism. Our data showed that the ubiquitination of p53 by PRL-1 expression was achieved by two independent pathways, by inducing the transcription of PIRH2 through EGR1 and by MDM2 phosphorylation. EGR1 has been shown to function in the transcriptional activation of p53 (Nair et al., 1997) , and we determined that p53 mRNA levels were reduced slightly in cells in which EGR1 expression was abrogated by siRNA (data not shown). We conclude that the induction of EGR1 by PRL-1 can simultaneously transactivate p53, as well as the negative regulator of p53, PIRH2. Conversely, we noted a downregulation of endogenous p53 protein as the result of PRL-1 expression, which suggests that MDM2 phosphorylation and PIRH2 induction may dominate the regulation of endogenous p53. Therefore, the reduction of p53 protein by PRL-1 was substantially greater in p53-negative cells lacking endogenous p53 transcription than in p53-positive cells because the endogenous p53 mRNA induced by EGR1 in p53-positive cells could be the p53 protein.
Earlier studies using DNA microarrays have implicated p53 in the PRL-1 transcriptional control. The presence of p53 is correlated with reduced PRL-1 expression in HCT116 colorectal cancer cells harboring wild-type p53 (HCT116 p53 ( þ / þ )) as compared with its isogenic p53 knockout counterpart HCT116 p53 (À/À) (Daoud et al., 2003) . However, in Figure 4 , we show that ectopic p53 expression in HCT116 p53 (À/À) cells induced an increase in the expression of PRL-1, and that the siRNA-mediated reduction of p53 levels in HCT116 p53 ( þ / þ ) cells caused a reduction in the levels of PRL-1 mRNA and PRL-1 protein. Using TFExplorer, a web-based prediction program for transcription factors, we identified a putative p53 binding site within intron 1 of the PRL-1 gene.
Collectively, our data establish a molecular mechanism between p53 and PRL-1, as is outlined in the schematic in Figure 5 . PRL-1 is one of the direct HCT116 p53 ( þ / þ ) cells were transfected with p53 siRNA ( þ , 10 nM) or control siRNA (À, 10 nM) and analysed through quantitative reverse transcription PCR (RT-PCR) (left panel) using primers specific for p53, PRL-1 and b-actin transcripts followed by agarose gel electrophoresis and western blotting (right panel) using antibodies against p53, PRL-1 and b-actin. (e) p53 binds the p53 response element of PRL-1 in vivo. HCT116 p53 ( þ / þ ) and HCT116 p53 (À/À) cells were subjected to chromatin immunoprecipitation (ChIP) analysis. Immunoprecipitation of p53 protein-DNA complexes was conducted with no antibody, control IgG or anti-p53 antibody. Input, 0.1% of the sonicated chromatin before immunoprecipitation. After immunoprecipitation, PCR amplification was conducted using primers specific for intron 1 of PRL-1. As controls, primers specific for the genomic region harboring the p53-responsive element of p21 (CDKN1A), a known p53 target gene, and primers specific for exon 4 of GAPDH were used. Displayed results are representative of three independent experiments.
PRL-1 is a new negative feedback regulator of p53 S-H Min et al transactivation targets of p53, thereby forming the negative feedback system exemplified by the p53-MDM2 pathway. We propose that elevated PRL-1 expression induces PIRH2 mRNA by the transcription of EGR1/2 and increases MDM2 phosphorylation through the PI3K signal pathway, thereby resulting in the degradation of p53 protein by means of ubiquitination and the inhibition of p53-mediated apoptosis. Unlike the common p53 targets associated with tumor suppressor function, PRL-1 is one of the oncogenic p53 targets, along with MDM2, PIRH2 and COP1 oncogenes. We believe our findings may contribute to our understanding of the functional roles of PRL-1 in the development and metastasis of various cancer types.
Materials and methods
Antibodies and reagents
Goat anti-PRL-1 polyclonal antibody was purchased from Everest Laboratory (Oxfordshire, UK ) were purchased from Cell Signaling Technology (Beverly, MA, USA). Where indicated, the cells were treated with 20 mmol/l of the PI3K inhibitor LY294002 (Cell Signaling Technology) for 6 h at 37 1C.
Cell culture
The HEK-293A human embryonic kidney cell, the HCT116 p53 ( þ / þ ) human colorectal cancer cell, the HCT116 p53 (À/À) human colorectal cancer cell, the HeLa human cervical carcinoma cell and the U2OS human osteosarcoma cell were grown in Dulbecco's modified Eagle's medium (Gibco-BRL, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (Hyclone, Logan, UT, USA), 100 IU/ml of penicillin and 100 mg/ml of streptomycin (Gibco-BRL). All cells were maintained at 37 1C in a humidified incubator under 5% CO 2 .
Luciferase reporter assay
To construct the PRL-1 promoter reporter with the p53 binding site (PRL1-p53-luc), a 151 bp promoter sequence of PRL-1 spanning þ 1634 through þ 1784 was amplified through PCR from human genomic DNA using the primer pair 5 0 -GCGAGCTCAGGCTCCACCTGGTAATTCG-3 0 and 5 0 -GCCTCGACTGGCCCAGAGAAAGGAC-3 0 . After digestion with SacI/XhoI, the PCR product was cloned into the pGL3-promoter vector (Promega, Madison, WI, USA). As a negative control, a luciferase reporter construct (PRL1 1.1 kb-luc) including 1.1 kb PRL-1 proximal promoter without the p53 binding site upstream of exon 1 was cloned into the pGL3-basic vector (Promega) after PCR amplification from human genomic DNA using the primer pair 5 0 -CTGACC AATGCTGGGATGTTCTACTGTTCTCC-3 0 and 5 0 -TTTG CCAGTGGTTTACCTTGGCACCTGG-3 0 , and digestion with KpnI/BglII. A mutant p21-luc (Mt p21-luc) construct (Westfall et al., 2003) without the p53 consensus sequence was cloned into the pGL3-basic vector (Promega) after the PCR amplification of the 1.3 kb promoter from the wild-type p21-luc reporter (Wt p21-luc) as reported (Westfall et al., 2003) .
For the luciferase reporter assay, pRGC-Luc (Huang et al., 1998 ), Wt p21-Luc (Resnick-Silverman et al., 1998 or Mt p21-luc reporter with or without PRL-1 (Flag-PRL-1; kindly provided from Dr Sung Hyun Kang and Dr Kwang Hee Bae) was transfected into cells using LipofectAMINE Plus (Gibco-BRL). For assays using PRL1-p53-luc and PRL1 1.1 kb-luc, the reporters were co-transfected with or without the p53 plasmid (Kim et al., 2007) . DNA (1 mg) mixed in all samples with 100 ng of the CMV-Ren plasmid (Promega) as an internal control was co-transfected into cells in six-well plates (Corning Inc., Corning, NY, USA). Luciferase assays were conducted 48 h after transfection using a Luciferase Assay Reagent kit (Promega) and a Lumat LB9507 luminometer (Berthold, Bad Wildbad, Germany). The values obtained were normalized with the Renilla luciferase activity.
RNA interference
The human p53, EGR1, PIRH2, MDM2 and control siRNA were purchased from Santa Cruz Biotechnology, and the human PRL-1 siRNA was synthesized by SamchullyPharm (Seoul, Korea). The sequence of the PRL-1 siRNA was as follows: PRL-1 sense-5 0 -CAGCAAGCAACUUCUGUA UUUGGdA-3 0 and PRL-1 antisense-5 0 -CUCCAAAUACA GAAGUUGCUUGCUGUU-3 0 . The siRNA was transfected into the cells using LipofectAMINE Plus (Gibco-BRL). 0 . The PCR products were separated through electrophoresis in 2% agarose gel and visualized by means of ethidium bromide staining. The synthesized first-strand cDNA was used for real-time PCR analysis using SYBR Green I. Product accumulation was monitored with an iCycler iQ RealTime detection system (Bio-Rad Laboratories, Hercules, CA, USA). The mean cycle threshold value (C t ) was calculated from triplicate samples, and applied to determine the level of gene expression. The sample DC t (SDC t ) value was calculated as the difference between the GAPDH C t and sample C t values.
Immunofluorescence analysis
Cells plated on coverslips pretreated with 0.1% gelatin in 12-well dishes were transfected with FLAG-PRL-1 and incubated for 2 days. The cells were washed with phosphate-buffered saline, fixed for 20 min in 4% (v/v) paraformaldehyde, incubated for 10 min at room temperature in phosphatebuffered saline containing 0.3% (v/v) Triton X-100 and further incubated for 10 min in 1% bovine serum albumin. Samples were subsequently incubated for 1 h with primary antibodies in the latter solution, washed three times in phosphate-buffered saline and incubated with Alexa Fluor 488-conjugated goat antibody against mouse IgG and Alexa Fluor 594-conjugated goat antibody against rabbit IgG (Molecular Probes, Eugene, OR, USA). The coverslips were mounted on glass slides in Vectorshield medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired using a Leica 6000 microscope.
In vivo ubiquitination assays Cells transfected with HA-ubiquitin were assessed for ubiquitination in vivo as described (Song et al., 2004) . In brief, after 18 h of transfection, the cells were treated with MG132 (1 mM/l) (Calbiochem, San Diego, CA, USA) for 6 h and then lysed for 10 min of incubation at 95 1C in two volumes of TBS (10 mM Tris-HCl (pH 7.5), 150 mM NaCl) containing 2% SDS. After the addition of eight volumes of 1% (v/v) Triton X-100 in TBS, the lysates were sonicated for 2 min and then incubated with protein G-agarose (Santa Cruz Biotechnology). After centrifugation, the lysates were then subjected to immunoprecipitation with anti-p53 antibody coupled to protein G-agarose. The beads were then washed once with 0.5 M LiCl in TBS and twice with TBS, boiled, and subjected to immunoblot analysis using anti-HA antibody.
Apoptosis assay
Cells undergoing apoptosis were quantified using a GFP system as described earlier Seong et al., 2007) . In brief, cells grown on sterile coverslips pretreated with 0.1% gelatin in 12-well dishes were transfected with pEGFP (Clontech, Palo Alto, CA, USA) coupled with expression vectors as indicated. After 24 h of transfection, the cells were treated for 24 h with 5-fluorouracil (3.8 mM), fixed with ice-cold 100% methanol and then washed three times with phosphatebuffered saline. The cells were then stained with a bisbenzimide (Hoechst 33258) and visualized under a fluorescence microscope. The percentage of apoptotic cells was calculated as the number of GFP-positive cells with apoptotic nuclei divided by the total number of GFP-positive cells.
ChIP assays
Chromatin immunoprecipitation assays in HCT116 p53 ( þ / þ ) or p53-deficient HCT116 p53 (À/À) cells were conducted using the ChIP Assay kit (Upstate Cell Signaling Solutions, Lake Placid, NY, USA) in accordance with the manufacturer's protocols. Cells cultured on 10 cm dishes were fixed with 1% (v/v) formaldehyde and then lysed in the provided lysis buffer containing protease inhibitors. After sonication and dilution with IP dilution buffer, the lysate was pre-cleared with salmon sperm DNA/protein A-agarose, incubated overnight at 4 1C with no antibody, mouse control IgG, monoclonal p53 antibody or EGR1 antibody (Santa Cruz Biotechnology) and the antibody-bound chromatin was precipitated with salmon sperm DNA/protein A-agarose. Finally, the DNA was isolated from the immunoprecipitated chromatin through phenol/chloroform extraction and then PCR-amplified using the following primer pairs: PRL-1 promoter: forward, 5 0 -AGGCTCCACCTGGTAATTCG-3 0 ; reverse, 5 0 -GTCCTTT CTCTGGGCCAGTC-3 0 ; GAPDH exon 4: forward, 5 0 -GTA TTCCCCCAGGTTTACAT-3 0 ; reverse, 5 0 -TTCTGTCTTCC ACTCACTCC-3 0 . p21 (WAF1/CIP1) promoter (the forward primer anneals 100 bp upstream of the 5 0 p53RE): forward, 5 0 -GCACTCTTGTCCCCCAG-3 0 ; reverse, 5 0 -TCTA TGCCAG AGCTCAACAT-3 0 (Weizer-Stern et al., 2007) . PIRH2 promoter: forward, 5 0 -GATACTTCGCCCTAGGTGTCAAACAG-3 0 ; reverse, 5 0 -AGATCACCAGTGACCTCTTCCTTGC-3 0 . SNAIL promoter: forward, 5 0 -TTTCCCTCGTCAATGCCACGCTC-3 0 ; reverse, 5 0 -CGAGCGAAGCGAGGCCTCTGCGAG-3 0 . All PCR reactions were conducted for between 30 and 33 cycles, and the PCR products were subjected to 1.5% agarose gel electrophoresis.
